DEA 7-OH Scheduling 2026: Status, Thresholds & Dates
Status checked July 14, 2026: DEA has published notices of intent concerning 7-hydroxymitragynine above specified thresholds and three related substances. The temporary scheduling orders are not yet effective, and no effective date has been announced. Any later order must be read as a separate controlling document.
The distinction between a notice of intent and an effective order matters. A notice announces the agency's intended action and the basis for it. Covered substances become subject to Schedule I controls only when the temporary scheduling order takes effect. Product names, marketing categories, and assumptions about the word kratom do not replace the threshold language in the federal document.
Current federal timeline
| Date | Federal action | What it means |
|---|---|---|
| July 1, 2026 | DEA announced that it had filed two notices of intent | The announcement described intended temporary scheduling; it was not the effective order |
| July 6, 2026 | The notices were scheduled for Federal Register publication | The 30-day statutory waiting period began from publication |
| August 5, 2026 or later | Earliest date on which DEA states it may publish the temporary order | The exact effective date will be the publication date of the later order, not an assumed date |
| After an order is published | Covered substances become subject to Schedule I controls | The order is temporary for two years, with a possible extension while permanent scheduling is considered |
What the 7-OH notice describes
The notice does not use a single retail-category rule such as every product called 7-OH or every product called MIT. It defines 7-hydroxymitragynine above specified thresholds and describes more than one type of material or article.
| Category in the notice | Threshold language summarized | Reading caution |
|---|---|---|
| Botanical material of Mitragyna speciosa | More than 0.050 percent 7-OH on a dry-weight basis | A botanical name alone does not establish the measured percentage |
| Alternative articles resulting from synthetic methods | More than 0.050 percent by the stated concentration measures or more than 1.00 milligram of 7-OH in the article | Both concentration and total-per-article language require attention |
| Plant-derived alternative dosage forms | The notice discusses extracts, concentrates, processed edibles, and pressed pills exposed to processing that leads to 7-OH above the stated concentration or per-article threshold | A format such as tablet or extract is not automatically inside or outside the rule without product facts |
A separate notice addresses mitragynine pseudoindoxyl, MGM-15, and MGM-16. Those substances should not be collapsed into mitragynine merely because the names share a root. The applicable notice and actual product identity must be read together.
What the notice does not automatically establish
- It does not mean that an effective temporary order was already in place on July 1 or July 6.
- It does not create a blanket federal approval for botanical kratom, MIT-labeled tablets, or extracts.
- It does not establish that every item marketed as kratom falls below a threshold.
- It does not establish that every MIT-labeled item is outside the covered definition.
- It does not replace state, county, city, shipping, payment, or other rules that may be broader or different.
- It does not turn a source-material report into a finished-product report.
How to evaluate a product without guessing
- Identify the exact product format and complete label name.
- Identify whether the available document analyzes botanical material, a concentrate, another source material, or the finished product.
- Match the sample or lot identifier and report date.
- Read the 7-OH result together with the units, LOD, and LOQ.
- Do not convert a source-material result into a finished-tablet result without documented manufacturing and finished-product evidence.
- Check the current federal document and the rules for the destination.
Where MIT products fit in this information system
MIT is shorthand for mitragynine in the Kratom Paradise catalog. It is not another name for 7-OH. The 7-OH vs Kratom vs MIT guide explains those terms, while the MIT Products Guide explains how tablet and extract listings are organized.
Kratom Paradise currently provides product-specific or source-material document context through the MIT Product Documents & COA Center. A linked report must be read according to its exact scope. It is not a serving instruction, safety assurance, legal opinion, or permanent guarantee for future inventory.
Frequently asked questions
Has DEA already scheduled 7-OH?
No, not as of July 14, 2026. DEA has published notices of intent. A temporary order would take effect if and when a later order is published.
Is August 5 automatically the effective date?
No. August 5 is the earliest date indicated by the notice's 30-day timing. The actual effective date will be the publication date of the later temporary order.
Does the notice exclude every MIT tablet or extract?
No blanket product-name conclusion is provided. The notice uses substance, concentration, processing, and per-article language. Product-specific facts and current legal review matter.
Does ND mean absolute zero?
No. ND means not detected under the method and reporting limits shown for the submitted sample. Read What ND Means on a 7-OH Lab Report for the full explanation.
Official sources
- DEA July 1, 2026 announcement
- Federal Register notice for 7-OH above specified thresholds
- Federal Register notice for mitragynine pseudoindoxyl, MGM-15, and MGM-16
- FDA consumer information about enhanced 7-OH products
- FDA and Kratom
Last reviewed July 14, 2026. This tracker provides general regulatory-document education and is not legal, medical, serving, or purchasing advice.